These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34213682)

  • 1. Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance.
    Uddin R; Darwish NHE; Mousa SA
    Curr Treat Options Oncol; 2021 Jul; 22(9):76. PubMed ID: 34213682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy.
    Sami SA; Darwish NHE; Barile ANM; Mousa SA
    Curr Treat Options Oncol; 2020 Jan; 21(1):3. PubMed ID: 31933183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities.
    Marchand T; Pinho S
    Front Immunol; 2021; 12():775128. PubMed ID: 34721441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia: 2019 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2018 Oct; 93(10):1267-1291. PubMed ID: 30328165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia.
    Morsink LM; Walter RB; Ossenkoppele GJ
    Blood Rev; 2019 Mar; 34():26-33. PubMed ID: 30401586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acute myeloid Leukemia].
    Braess J
    Dtsch Med Wochenschr; 2016 Nov; 141(24):1748-1751. PubMed ID: 27835920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in pathogenesis research and challenges in treatment development for acute myeloid leukemia.
    Yamaguchi H
    Int J Hematol; 2024 Oct; 120(4):414-416. PubMed ID: 39225969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updates on targeted therapies for acute myeloid leukaemia.
    Kayser S; Levis MJ
    Br J Haematol; 2022 Jan; 196(2):316-328. PubMed ID: 34350585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Future of Targeting FLT3 Activation in AML.
    Leick MB; Levis MJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia.
    Zeng Z; Liu W; Tsao T; Qiu Y; Zhao Y; Samudio I; Sarbassov DD; Kornblau SM; Baggerly KA; Kantarjian HM; Konopleva M; Andreeff M
    Haematologica; 2017 Sep; 102(9):1537-1548. PubMed ID: 28659338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?
    Megías-Vericat JE; Martínez-Cuadrón D; Solana-Altabella A; Montesinos P
    Expert Rev Hematol; 2020 Oct; 13(10):1057-1065. PubMed ID: 32869672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment options for older unfit patients with acute myeloid leukemia.
    Tang H; Jia S; Bi L; Jia W; Gao G
    Future Oncol; 2021 Mar; 17(7):837-851. PubMed ID: 33522289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of post-transplant relapsed acute myeloid leukemia with FLT3 internal tandem duplication using the combination of induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Report of three cases.
    Campregher PV; Mattos VRP; Salvino MA; Santos FPS; Hamerschlak N
    Einstein (Sao Paulo); 2017; 15(3):355-358. PubMed ID: 28746590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New agents for the treatment of acute myeloid leukemia.
    Tallman MS
    Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
    Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Relapsed Acute Myeloid Leukemia.
    Thol F; Ganser A
    Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
    Pelosi E; Castelli G; Testa U
    Blood Cells Mol Dis; 2015 Dec; 55(4):336-46. PubMed ID: 26460257
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Naqvi K; Ravandi F
    Leuk Lymphoma; 2019 Aug; 60(8):1866-1876. PubMed ID: 30997851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia.
    Wang J; Tomlinson B; Lazarus HM
    Curr Treat Options Oncol; 2023 Jul; 24(7):770-801. PubMed ID: 37195589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.